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Introduction
Aurora Health Care’s Heart & Vascular program comprises more than
100 cardiovascular specialists offering services at hospitals and clinics
throughout eastern Wisconsin and northern Illinois.

Cardiovascular subspecialists provide cutting-edge care to prevent,
diagnose, and treat patients with heart and vascular disease in a 		
high-volume and high-quality clinical practice that is supported by
robust education and research programs.

Aurora’s cardiovascular division includes collaborative subspecialty
clinics that focus on structural heart disease, peripheral vascular disease,
electrophysiology, channelopathies, hybrid AF (AF) treatment,		
congestive heart failure, and pulmonary hypertension.

Aurora St Luke’s Medical Center was ranked in the top 50 nationally in
Cardiology and Heart Surgery by U.S News & World Report, and was
recognized for using evidenced-based guidelines to improve the quality
of care for patients with heart disease and stroke by the American Heart
Association/American Stroke Association.

Collaborative efforts between interventional cardiologists and 		
cardiovascular surgeons have resulted in the largest transcatheter valve
program in the state, where over 1,000 transcather aortic valve 		
replacement (TAVR) procedures were performed. Aurora St. Luke’s also
offers mitral clip technology and is participating in transcatheter mitral
valve research for degenerative mitral regurgitation. In addition, Aurora
St. Luke’s is a training center for TAVR technology.

Our electrophysiology program is one of the oldest and largest 		
programs in the nation. We have trained physicians from all over		
the world and provide cutting-edge technology and treatment for
all types of arrhythmias. Our program is one of few centers in the US
offering hybrid AF catheter ablation, improving the success rate 		
for this procedure. We are a training center for this and many other 		
electrophysiology technologies.

The center’s transplant program is among the top in the country. The
center has reached over 890 transplants and over 785 ventricular assist
device implants. We continue to have clinical outcomes in the upper
quartile for quality outcomes.

Through the use of the da Vinci Surgical System, we have one of the
largest thoracic robotic surgery programs in the country. In 2016, we have
performed over 1,000 thoracic robotic surgeries, and we continue to be an
international training center for this technology.

In 2016, 24 fellows-in-training participated in Aurora Health Care’s
graduate medical education program in the areas of Cardiovascular
Disease, Interventional Cardiology, Electrophysiology, and Heart 		
Failure. The program consists of basic, translational, and clinical 		
research components.

Aurora cardiovascular specialists have a long history of publishing
cutting-edge abstracts, articles in peer-reviewed medical journals, and
chapters in medical textbooks. In 2016, Aurora authors had 71 abstracts
and 58 articles and book chapters published.
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Message from Our Leadership

Aurora Health Care’s Heart & Vascular Service Line is honored
to provide this publication highlighting our commitment to
the quality of the cardiovascular services we provide for
preventing, diagnosing, and treating heart and vascular disease.
We are dedicated to using state-of-the-art technology and the latest advancements
in clinical research to provide the best treatment options in the management of
cardiovascular disease for the patients we serve.
Our world-renowned specialists use the most advanced tools and technologies
currently available in the industry.
Daniel O’Hair, MD

Our patients benefit from having a team of experts who collaborate in providing
the best treatment options, which may not be available in all health care settings.
We continually monitor our quality performance by participation in national registries
to benchmark our performance and the services that we provide. Our multidisciplinary
core improvement teams are dedicated to providing the highest quality of care possible.
Aurora Health Care is committed to transparency in reporting the quality of our services.
If you have any questions or feedback, please contact heartandvascular@aurora.org.
Sincerely,
Daniel O’Hair, MD
Jasbir Sra, MD

Jasbir Sra, MD

5

At Aurora Health Care, we are fortunate to be in
the quality-of-life business. We help people live
well. That’s our purpose, and it drives everything
we do as an integrated not-for-profit health care
provider serving more than 90 communities and
30 counties throughout eastern Wisconsin and
northern Illinois.
Our patients enjoy care that is coordinated across a comprehensive
network of facilities, services, and providers. Our 15 hospitals and 159
clinics are bringing the latest technologies to communities
throughout eastern Wisconsin. From primary and specialty care to
hospitals, pharmacies, labs, and the largest home care organization
in Wisconsin, we’ve developed a model of care that improves quality,
makes care more efficient and affordable, and enhances every
patient’s health care experience. Today, we are Wisconsin’s largest
private employer with more than 31,000 amazing caregivers, including
1,800 employed physicians. We are governed by a community board
of directors, business and community leaders who offer their expertise
and resources to help guide our work today and prepare us for the
future. As caregivers, we feel privileged to serve more than 1.2
million patients every year and to experience 7.8 million
patient encounters.
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Our Services

Aurora’s Heart & Vascular Program prides itself on treating the most heart
patients in Wisconsin. Our studies confirm that high-risk patients have better
outcomes at hospitals that perform high volumes of complex procedures.
Aurora Health Care is dedicated to excellence in every aspect of heart,
vascular, and thoracic care, including research, wellness, prevention,
diagnosis, treatment, and follow-up care. Our world-renowned specialists
and subspecialists provide cutting-edge care to prevent, diagnose, and treat
patients with heart and vascular disease. We are proud of our national
reputation for offering solutions for patients with the most complex
conditions who have been told they have no other option.

Wisconsin

Our
Service
Areas

Michigan

= Hospital
= Aurora Psychiatric Hospital.
Behavioral Health is a Patient
Service Area without
geographical boundaries

Green Bay,
Manitowoc
& Marinette

North Region

Aurora’s Thoracic Surgery program prides itself on providing a
multidisciplinary approach to treating patients. Our minimally invasive
techniques reduce length of stay, decrease pain, and allow for a shorter
recovery time. Additionally, Aurora’s robot-assisted thoracic surgery
program is the busiest in Wisconsin and the Midwest. Aurora Grafton
Medical Center is one of 10 approved robotic surgery mentor sites
in North America.

Oshkosh
& Fond du Lac

Greater Milwaukee North
& Sheboygan

Central Region

Waukesha
& Jefferson

Greater
Milwaukee South

Wisconsin
Illinois

Burlington
& Walworth
Racine,
Kenosha
& Northern
Illinois

South Region
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Accreditations & Recognitions

Aurora BayCare
Medical Center
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•

American Association of Cardiovascular and Pulmonary Rehabilitation
(AACVPR) Certification – Cardiovascular & Pulmonary

•

American College of Cardiology (ACC) Foundation’s National Cardiac Data
Registry® (NCDR) ACTION Registry® Get With The Guidelines™ – Platinum
Performance Achievement Award

•

American College of Cardiology – Nurse Navigator Award

•

American Heart Association (AHA) Mission: Lifeline® Accreditation for
Heart Attack Receiving Center - Silver Award

•

AHA Get With The Guidelines® Gold Plus Award for Stroke and Target
Stroke Elite Plus Honor Roll

•

AHA Get With The Guidelines® for Heart Failure – Gold Plus Achievement
Award

•

AHA Get With The Guidelines® for AFIB – Silver Achievement Award

•

Blue Cross Blue Shield Designated Blue Distinction® Center of Cardiac Care

•

Truven Health 100 Top Cardiovascular Hospitals

•

UnitedHealth Premium® Cardiac Specialty Center – Cardiac Care

•

UnitedHealth Premium® Cardiac Specialty Center – Cardiac Surgery

•

UnitedHealth Premium Cardiac Specialty Center – Heart Rhythm Disorders

Aurora Memorial
Hospital of Burlington

•

AHA Get With The Guidelines® Gold Plus Award for Stroke

•

AHA Get With The Guidelines® Gold Plus Award for Heart Failure Care and
Target: Heart Failure Honor Roll

•

Top Performing Hospital by The Joint Commission for Heart Attack
123

Aurora Medical
Center in Grafton

Aurora Medical
Center in Kenosha

•

AHA Get With The Guidelines® Gold Plus Award for Heart Failure
and Target: Heart Failure Honor Roll

•

AHA Get With The Guidelines® Gold Plus Award for Stroke and
Target: Stroke Honor Roll - Elite

•

American Association of Cardiovascular and Pulmonary			
Rehabilitation (AACVPR) Certification - Cardiovascular

•

Blue Cross Blue Shield Designated Blue Distinction® Center of
Cardiac Care

•

AHA Get With The Guidelines® Gold Plus Award for Heart Failure

•

American Association of Cardiovascular and Pulmonary 		
Rehabilitation (AACVPR) Certification - Cardiovascular
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Accreditations & Recognitions

Aurora Lakeland
Medical Center

•

AHA Get With The Guidelines® Gold Plus Award for Stroke

•

AHA Get With The Guidelines® Gold Plus Award for Heart Failure Care
and Target: Heart Failure Honor Roll

•

Society of Cardiovascular Patient Care - Chest Pain Accreditation
123

Aurora Sheboygan
Memorial Medical Center

Aurora Sinai
Medical Center
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•

AHA Get With The Guidelines® Gold Plus Award for Stroke and Target:
Stroke Honor Roll - Elite

•

American Association of Cardiovascular and Pulmonary Rehabilitation
(AACVPR) Certification - Cardiovascular & Pulmonary

•

AHA Get With The Guidelines® Gold Plus Award for Heart Failure

•

AHA Get With The Guidelines® Gold Plus Award for Stroke and Target:
Stroke Honor Roll

Aurora St. Luke’s
Medical Center

•

American College of Cardiology Foundation’s NCDR® ACTION Registry® Get
With The Guidelines™ – GOLD Performance Achievement Award

•

AHA Get With The Guidelines® Gold Plus Award for Heart Failure and Target
Gold Heart Failure – Honor Roll

•

AHA Get With The Guidelines® Gold Plus Award for Stroke and Target Gold
Stroke – Honor Roll Elite – Plus

•

AHA Mission: Lifeline® Gold Plus Award for Heart Attack Receiving Center

•

American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)
Certification - Cardiovascular & Pulmonary

•

Blue Cross Blue Shield Designated Blue Distinction® Center of Cardiac Care

•

Society of Cardiovascular Patient Care – Chest Pain Accreditation

•

Accreditation for Cardiac Excellence (ACE) – PCI and PVI

•

The Joint Commission Advanced Certification in Ventricular Assist Device

•

The Joint Commission Advanced Certification in Comprehensive Stroke

•

Magnet Recognition for Nursing Excellence – Fourth Time Recognition

•

US News and World Report Nationally Ranked #31 for Cardiology and
Heart Surgery

•

US News and World Report Regionally Ranked #3 in Wisconsin
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Accreditations & Recognitions
Aurora St. Luke’s
South Shore

Aurora Medical
Center in Summit

Aurora Medical Center
in Manitowoc County
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•

AHA Get With The Guidelines® Silver Plus Award for Stroke and
Target Gold Stroke – Elite Plus Honor Roll

•

AHA Target Silver Plus Award for Heart Failure

•

AHA Mission: Lifeline® NSTEMI Early Adopter

•

AHA Get With The Guidelines® Gold Plus Award for Stroke

•

American Association of Cardiovascular and Pulmonary 		
Rehabilitation (AACVPR) Certification – Cardiovascular

•

Blue Cross Blue Shield Designated Blue Distinction® Center of
Cardiac Care

•

AHA Get With The Guidelines® Gold Plus Award for Stroke and Target
Gold Stroke – Honor Roll

•

American Association of Cardiovascular and Pulmonary Rehabilitation
(AACVPR) Certification – Cardiovascular & Pulmonary

Aurora Medical
Center in Oshkosh

Aurora West Allis
Medical Center

•

AHA Get With The Guidelines® Silver Plus Award for Heart 		
Failure and Target Gold Heart Failure – Honor Roll

•

AHA Get With The Guidelines® Gold Plus Award for Stroke

•

American Association of Cardiovascular
and Pulmonary 		
123
Rehabilitation (AACVPR) Certification – Cardiovascular

123
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System Cardiovascular Overview
Interventional
Cardiology

Cardiovascular
Surgery
Coronary Artery Bypass Graft 		

941

Heart Catheterization

9,051

Aortic Valve (AV) Replacement		

718

Myocardial Biopsy

426

Mitral Valve (MV) Replacement		

114

2,354

Valve Replacement/Other			

22

Percutaneous Coronary
Artery Intervention (PCI)

Aortic Valve Repair			

15

PCI with Stent

2,206

Mitral Valve Repair			

39

PCI with Atherectomy

112

Valve Replacement/Other			

23

Cardiac Ablation (Open)			

212

VAD
& Transplant

14

Implantable Ventricular
Assist Device (VAD)

39

Heart Transplants

25

Transcatheter Aortic Valve Intervention

334

Transcatheter Mitral Valve Intervention

26

Percutaneous Balloon Valvuloplasty

43

PFO/ASD Closure

111

Open

66

Closed

45

Cardiac
Electrophysiology
Electrophysiology Study		

1,151

Cardiac Mapping		

880

Cardioversion (Atrial)		

1,530

Percutaneous Cardiac Ablation		

999

Pacemaker Implant		

1,138

Lead Extraction

117

Implantable Cardioverter 		
Defibrillator (ICD)

904

Vascular
Peripheral Vascular Intervention (PVI)

Cardiac Imaging
2,360

Cardiac MRI

528

PVI with Stent

1,032

Coronary CTA

494

PVI with Atherectomy

1,328

Echocardiogram, Transthoracic

68,952

Intracranial Intervention

69

Echocardiogram, Transesophageal

2,708

Precerebral Intervention

-

Echocardiogram, Stress

7,518

Carotid Artery Stenting

34

Myocardial Perfusion

16,863

Stenting of Other Precerebral Artery

3

Cardiac PET

768

Abdominal Aortic Aneurysm (AAA) Repair

168

Endovascular

147

Open

21

Thoracic Aortic Aneurysm (TAA) Repair

292

Endovascular

37

Open

255

Carotid Endarterectomy

327

Other Endarterectomy

168

Lower Extremity Bypass

203

Source: Aurora Health Care EMR ICD - 10/CPT billing
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CARDIOVASCULAR
SURGERY

16

Aurora’s heart & vascular program is a premier place for high-risk
surgical candidates. Our second opinion program gives high-risk
patients who have been declined by other organizations another
chance for treatment with our expert surgical team. The Aurora
Cardiovascular surgery team collaborates with a
multidisciplinary team to provide the highest quality of care and
superior results to every patient every day. We combine
evidence-based practice with the most highly trained and
experienced physicians, advanced practice practitioners,
nationally ranked pulmonary services, critical care specialists,
and allied health professionals to provide innovative care for
our patients.

BY THE
NUMBERS
Cardiac Surgery Volumes

•

Ascending aortic surgery

•

Arch surgery

•

Aortic root replacement

•

Atrial myxoma surgery

•

Carotid endarterectomy

•

Chronic total occlusion procedures

•

Coronary artery bypass surgery

•

Endovascualr harvest techniques

•

Extracorporeal membrane oxygenation (ECMO)

•

Heart transplantation

•

Hybrid aortic operations

Source: STS Cardiac Surgery Registry

We offer surgical and collaborative services including:

Volume

Cardiovascular surgery provides referring physicians and
patients with options for receiving highly specialized services
and access to the latest technological advancements. Our team
has integrated a preoperative anemia clinic to minimize
blood utilization. Additionally, we have a preoperative pharmacy
consult team to maximize medications in order to prevent
arrhythmias. Our services include a high-risk team that
includes cardiologists, anesthesiologists, and cardiovascular
surgeons who in turn offer opinions regarding surgery versus
high-risk angioplasty.

Year
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•

Hybrid surgery - AF

•

ICD/pacemaker implantation

•

Preoperative consultation

•

Redo Surgery

•

Robot-assisted procedures

•

Robotic Heller myotomy

•

Robotic mitral valve surgery

•

Second opinion

•

Thoracoabdominal aneurysm repair

•

Thoracic graft stenting

•

Thoracic surgery (see Thoracic Surgery section)

•

Total artificial heart

•

Transcatheter heart valves

•

Valve repair (Allows the patient to maintain their current valve but
corrects the defect. This is a highly trained procedure that has better
outcomes than replacing the valve.)

•

Valve replacement surgery (with options of mechanical versus
tissue valve)

Isolated CABG Postoperative Information
STS Expected

Aurora

•

Complicated ICD lead placements (extractions)

•

MAZE procedures for atrial fibrillation

•

Off pump coronary artery bypass (bypass on a beating heart.
This decreases length of stay and postoperative complications.)

•

Ventricular assist devices (VADs)

Our comprehensive team offers the newest surgical techniques, including
robot-assisted surgery, beating heart surgery (off-pump), and minimally
invasive surgeries. We offer a preoperative evaluation with our anemia
clinic to minimize the use of blood products intraoperatively. Our
pharmacists assess patients prior to surgery for medications to prevent
irregular rhythms after surgery. The physician assistants are trained in the
newest technology for endovascular vein harvest, which allows for small
incisions and quicker healing.
Source: STS Cardiac Surgery Registry
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Aurora Health Care’s heart surgeons perform more heart surgeries than any other health care organization in Wisconsin. The team’s experience offers our
patients a high skill level and a multidisciplinary approach to care combined with the latest technological advances.
Aurora has a dedicated multidisciplinary improvement team that meets regularly to discuss quality outcomes, best practices, and improvement opportunities.
Our team-based approach to care has improved our care delivery and patient satisfaction.

Isolated CABG In-Hospital Outcomes
Aurora

STS Expected

Source: STS Cardiac Surgery Registry

Isolated CABG Discharge Medications
Aurora

STS

Source: STS Cardiac Surgery Registry

Isolated procedures are those procedures performed without any other surgery. The Society of Thoracic Surgeons (STS) has developed a comprehensive
rating system for the quality of coronary artery bypass grafting (CABG) surgery. Approximately 12-15% of hospitals received the “3 star” rating for CABG and
valve surgeries, which denotes the highest category of quality. Our Aurora hospitals have achieved and continue to work diligently to achieve this ranking.
Our nurse practitioners are instrumental in assuring patients are on the correct medications after surgery and upon discharge. Aurora Health Care has been
99-100% compliant on the STS process measures that include perioperative beta blocker, use of the internal mammary artery, and the use of beta blocker,
statin, and aspirin at discharge.
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ISCHEMIC HEART
DISEASE

Extubated in OR

Initial Ventilation <6 Hours
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Coronary artery disease (CAD), also called ischemic heart disease, is
one of the most prevalent types of heart disease, affecting nearly 17
million Americans.
Our program offers state-of-the-art technology, opportunities to
participate in clinical trials, and adherence to clinical best practices,
such as same–day discharge after a coronary angioplasty and radial
artery approach. Post-discharge care includes an extensive cardiac
rehabilitation program.
Aurora Health Care is committed to adhering to the ACC/AHA
performance measures in order to provide defect-free care for
our acute myocardial infarction (AMI) patient population. We
continue to be above the national average.

BY THE
NUMBERS
Door-to-Balloon, Minutes (Median)

Time-to-treatment is a critical factor in outcomes for patients with
ST-segment elevated myocardial infarction. Our STEMI teams
have achieved response times well under national targets and
significantly outperform regional and national averages.

60

90

Aurora St. Luke’s Medical Center was
one of the first centers to establish a

24/7/365 in-house cardiology

Source: ACC-NCDR CathPCI Registry

Acute Myocardial Infarction - Defect-Free Care

program for heart attack care to restore
blood flow in less than 60

minutes

to reduce permanent heart damage.
Through this program, we continue to

94.6%

73.9%

achieve some of the shortest times to
reperfusion in the country.
Source: ACC-NCDR ACTION Registry
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BY THE
NUMBERS

Patients with complex medical backgrounds present greater challenges for
PCI procedures. In 2016, patients who had PCI at Aurora Health Care had
more co-morbidities than patients at comparable hospitals.
In 2016, Aurora Health Care treated a variety of patients with
complex procedure findings in comparison to other hospital systems
across the nation.

Risk Factors Among Patients Undergoing
PCI Procedures
2016
Aurora
US Registry
0

25

50

PCI Procedure Findings
Aurora
US Registry

%
6

Age _ 80 years

Diabetes
Mellitus

3.3
2

Peripheral
Arterial Disease

1.9

2.0

0

Cerebrovascular
Disease

Left Main with RCA
(triple vessel disease)

Our cardiovascular specialists at Aurora Health Care offer the latest
techniques for treating chronic total occlusion (CTO) of the arteries
supplying the heart. By precisely guiding a catheter to the site of the
blockage and employing a combination of balloon angioplasty and stent
placement, specialists re-establish the blood supply to the heart muscle.
The CTO procedure restores quality of life for patients who might not be
candidates for coronary bypass surgery.

Prior MI

Prior PCI

With the growing body of evidence that transradial catheter insertion
is associated with lower complication rates compared to the traditional
transfemoral technique, there is an upward trend in radial use for Aurora
Health Care. Radial approach allows patients to be safely discharged the
same day of the procedure and has increased patient satisfaction, while
lowering the cost associated with length of stay.

Prior CABG

Prior Heart
Failure
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2.7

Source: ACC-NCDR Cath Registry

Source: ACC-NCDR Cath Registry

4

Chronic Total Occlusion
Procedure Volumes
2014 - 2016

Radial Access for Patients
Undergoing PCI Procedures
2013 - 2016
40%

150
100

20%

71

50
8%

0

0%
Source: ACC-NCDR CathPCI Registry

Source: CathPCI
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CARDIAC RHYTHM
DISORDERS
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The Cardiac Electrophysiology division of Aurora Health Care is
internationally renowned for its pioneering work in electrophysiology
since its inception in the early 1980s. The group has grown to one of the
largest in the country and continues to perform cutting-edge
electrophysiology procedures, participate in basic, translational, and
clinical trials, present new science at major national and international
symposia and meetings, and publish in peer-reviewed scientific journals.
One area of particular importance is sudden cardiac death, which claims
more than 300,000 lives annually in the United States, with the majority
caused by life-threatening heart rhythms—the cause of “cardiac arrest.”
Today such patients can be managed through a variety of treatment
options offered at Aurora Health Care, including medications, ablative
therapy (controlled heart tissue destruction to eliminate abnormal and
dangerous heart beats), and multiple implantable cardiac defibrillator
(ICD) options.
Also of note, the number of people in the United States with atrial
fibrillation (AF) is increasing at epidemic proportions. AF is the most
common arrhythmia in clinical practice and it affects millions of lives
each year with serious and often life-threatening complications
including heart failure, stroke, and death. Aurora Health Care offers
patients with AF a variety of treatment options tailored to their specific
needs, ranging from simple medication options to complex coordinated
procedural solutions. In fact the first “hybrid” AF ablation in
Wisconsin—a combined surgical and catheter-based technique—was
performed in Aurora Health Care.
At Aurora Health Care we strive to always remain on the cutting edge
of technology and innovation in cardiac rhythm management so that
we can provide the most comprehensive management options to our
patients, helping them live better and providing them the best care.
Along with various types of outpatient monitoring and testing, our
diagnostic and interventional tools include:

•

Electrophysiology studies

•

Cardioversions

•

Tilt table testing

•

Catheter ablation, including ablation for atrial fibrillation and other
complex arrhythmias

•

Device therapy

•

Drug therapy

•

Hybrid surgery

•

Intraoperative 3-dimensional mapping

•

Channelopathy clinic

•

Device optimization clinic

EP PROCEDURES
The electrophysiologists at Aurora Health Care provide patients with
individualized treatment approaches using cutting-edge technology to
eliminate or manage their heart rhythm disorders. Aurora Health Care
has performed more ablation and device-related procedures than other
Wisconsin health care systems. Aurora electrophysiologists implant
pacemakers and defibrillators to treat cardiac rhythm disorders. A special type of pacemaker or defibrillator called a cardiac resynchronization
therapy (CRT) device may also be implanted to treat heart failure in a
select group of patients.
Patients with irregular or rapid cardiac rhythms may benefit from a procedure that ablates or blocks the electrical impulse or heart beats when
they are out of control and causing heart fluttering. Aurora Health Care
also performs tilt table testing to diagnose autonomic dysfunction that
may lead to syncope (fainting).

25

BY THE
NUMBERS
Electrophysiology Lab
Procedure Volumes
2016
0

200

400

600 800

1000 1200 1400

AF ABLATION
Our electrophysiologists use multiple approaches to control or eliminate
AF. In addition to drug therapy, the electrophysiologists use ablation
with radiofrequency (heat) or cryoablation (cold) in conjunction with
specialty three-dimensional mapping to achieve the best outcomes for
ablating AF. Aurora Health Care is one of few providers in Wisconsin to
offer a hybrid (surgical and minimally invasive) ablation procedure for
patients with AF that has not been eliminated by drug therapy or
conventional ablation.
Aurora electrophysiologists also can implant a very small device (loop
recorder) under the skin that can monitor the patient continuously to
record AF episodes the patient may not be aware of. This can be easily
checked in the office and helps the physicians evaluate the effectiveness
of therapy for the patient.
Other Innovations
Aurora Health Care’s electrophysiologists are implanting leadless pacemakers. A percutaneous (non-surgical) approach is used to place the
device, which does not require a standard pacemaker lead in the heart.
This is particularly beneficial for nephrology patients and young athletes.

AUTONOMIC CENTER
In collaboration with neurologists and other specialists, the
electrophysiology service evaluates patients with dysautonomia.
Dysautonomia is an umbrella term used to describe various conditions
that cause a malfunction of the autonomic nervous system (ANS). The
ANS is made up of two branches: the sympathetic nervous system
(SNS) and the parasympathetic nervous system (PNS). The SNS controls
the more active “fight or flight” responses, such as increasing heart rate
and blood pressure. The PNS can be thought of as the “rest and digest”
part of the autonomic nervous system, as it slows down the heart rate
and aids in digestion.

Abbreviations: AF – atrial fibrillation, AFL – atrial flutter, SVT – supraventricular tachycardia, VT – ventricular tachycardia
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People living with various forms of dysautonomia have trouble regulating these
systems, which can result in symptoms such as lightheadedness, fainting, unstable
blood pressure, tachycardia or bradycardia, gastroparesis, and more.
Dysautonomia can occur as a primary disorder or in association with other
conditions, such as diabetes, rheumatoid arthritis, and Parkinson’s disease. Some
of the more common forms of dysautonomia include neurocardiogenic syncope
(NCS, sometimes called vasovagal syncope), postural orthostatic tachycardia
syndrome (POTS), and orthostatic intolerance (OI). Some of the less common
forms of dysautonomia include pure autonomic failure (PAF), multiple system
atrophy (MSA), familial dysautonomia, baroreflex failure, autoimmune autonomic
ganglionopathy, and dopamine beta hydroxylase deficiency.
There currently is no cure for dysautonomia, but secondary forms such as Sjogren’s
syndrome-induced autonomic neuropathy or diabetic autonomic neuoropathy
may improve with treatment of the underlying disease. There are many treatments
available to improve quality of life, including medications and lifestyle changes/
adaptations geared toward the type of dysautonomia and unique health
situation of the patient. Physical therapy and cardiac rehabilitation are available.
Tests offered may include tilt table testing and autonomic lab testing, as well as
various lab analyses.
Research protocols for POTS and neurogenic orthostatic hypotension are currently
enrolling subjects.

CARDIAC CHANNELOPATHY CENTER
Channelopathies pose a unique diagnostic and management challenge because
the abnormalities are molecular, consequences are severe, and treatment may have
significant physical and psychological impacts. Channelopathies may affect family
members and generations of family members. In particular, genetic testing results
require careful interpretation and have implications for family screening, planning,
and counseling. Such patients are best served through a dedicated clinic focused
and sensitive to their unique needs.
In 2016, the Aurora Cardiac Channelopathy Center saw 76 new patients for
inherited sudden death arrhythmia syndromes, such as long QT syndrome,
Brugada syndrome, and idiopathic ventricular fibrillation, as examples. 72 patients
received genetic testing and interpretation along with family and genetic
counseling. In addition, these families have now had other family members with
similar genetic predisposition to sudden death identified through cascade
screening. The center has actively engaged these family members to address their
associated risks as well and to educate them on their clinically and genetically
unique needs.

Electrophysiology Lab
Atrial Fibrillation Ablation Volumes
2011-2016
400
200
0
2011

2012

2013

2014

2015

2016

Source: STS Cardiac Surgery Registry
Sites: Aurora BayCare, Grafton, St. Luke’s & Summit
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VALVE PROGRAM
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Aurora Health Care performs more than

650 heart valve surgeries per year,
including repair and replacement of the
mitral valve, aortic valve, pulmonic valve,
and tricuspid valve.

Aurora Health Care uses a comprehensive, multidisciplinary approach
to performing complex, technologically advanced heart valve surgery.
The depth of surgeon experience allows us to perform high-risk, secondand third-time reoperations, as well as surgeries to patients who were
deemed inoperable at other facilities.
The Aurora Transcatheter Heart Valve program specializes in the
evaluation and treatment of high-risk patients who require careful
planning and assessment prior to treatment options. The team of
specially trained cardiologists and cardiothoracic surgeons, nurses,
researchers, and other experts works together to determine the best
course of treatment for each patient and offers them access to clinical
trials and cutting-edge therapies for aortic and mitral valve disorders.
Since the inception of the program in June 2011, thousands of patients
have been evaluated with more than 1,000 patients undergoing
transcatheter aortic valve replacement (TAVR).

Valve Program Evaluations
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Medical
Management/
Other

Surgical AV
Replacement

Mitral Clip

Surgical MV
Replacement

Surgical MV
Repair

Source: Valve Program Database

Owing to the minimally invasive nature of many of the treatment options available, patients who are not candidates for
open-chest surgery may be eligible for treatment with a catheter-based system. Through a multidisciplinary approach
focused on treating patients with the best technologies available, the transcatheter heart valve team has been able to
achieve excellent outcomes for patients, restoring their health, and improving their quality of life.
Among the options available for the treatment of severe aortic stenosis is transcatheter aortic valve replacement
(TAVR). This treatment is utilized for patients who are at high risk for surgical aortic valve replacement. For treatment
of mitral regurgitation, we have the minimally invasive mitral clip therapy, which also is placed without opening the
chest and is utilized for patients who are not a candidate for open-heart surgery and mitral valve repair or replacement.
We have multiple clinical trials going on at Aurora St. Luke’s Medical Center giving our patients multiple options for
treating their valve disease. Aurora Health Care recognizes the importance of technological advancement in the
treatment of vascular disease and is proud to offer these cutting-edge treatments to our patients.
The Valve Program has grown considerably with the expansion of our structural heart program, inclusive of TAVR and
transcatheter mitral valve replacement (TMVR), mitral clip, and other valve treatment options.
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THORACIC
SURGERY

32

Aurora Cancer Care’s multidisciplinary team
brings together a group of dedicated thoracic
cancer specialists, including thoracic surgeons,
pulmonologists, medical oncologists, radiation
oncologists, cancer care coordinators, cancer
rehabilitation specialists, and specialized
nurses to provide personalized care using the
latest treatments and technologies. The thoracic
surgeons at Aurora Health Care treat patients
with a wide variety of conditions pertaining to
the lung, diaphragm, esophagus, and chest.
The team specializes in malignant diseases including lung and
esophageal cancer, mesothelioma, mediastinal masses, and tumors
of the chest wall, as well as benign processes including
pneumothoraxes, pleural effusions, empyema, achalasia, and
diaphragmatic hernias. In addition, technological advancements
have led Aurora Health Care’s thoracic surgeons to perform rib
plating, bronchial and tracheal stenting, and robot-assisted
surgery. Our comprehensive program offers cutting-edge
techniques and screenings for patients from all 50 states.

BY THE
NUMBERS
General Thoracic Surgery Volumes

693

758

647

885

Ninety-two percent of our thoracic surgery patients receive
minimally invasive surgery for their cancer. According to US News
and World Report, Aurora received the ‘best’ ranking for
survival 30 days after thoracic surgery as well as the ‘best’
ranking for preventing prolonged hospitalizations. Additionally,
Aurora Health Care treats more lung cancer than any other health
care system in Wisconsin. Aurora Thoracic Surgery is proud to
provide a highly qualified and effective treatment team for
thoracic surgery patients.
Our robot-assisted thoracic surgery program is nationally
recognized. Dr. William Tisol leads the busiest robot-assisted
thoracic surgery practice in Wisconsin and the Midwest. Aurora
Medical Center in Grafton serves as an observation center for the
state-of-the-art Intuitive Surgical da Vinci XI® surgical system.

993

1,029

Source: STS Thoracic Registry (St. Luke’s, Grafton, & Summit)

Surgeons and their teams come from all over the country to observe
robot-assisted thoracic surgery. Aurora Medical Center at Grafton is one
of 10 approved thoracic robotic surgery mentor sites in North America
and one of two in the Midwest hosting over 50 guests per year.
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Thoracic Surgery by Type
Although the thoracic team specializes in a
variety of disease processes, the majority
of procedures performed are pulmonary.
The majority of thoracic surgeries		
performed are done with a minimally
invasive approach which decreases length
of stay and significantly reduces the pain
associated with thoracic surgery.
Source: STS Thoracic Registry
(St. Luke’s, Grafton, & Summit)
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Video-Assisted (VATS) Lobectomies
STS

Aurora

LOBECTOMIES
The majority of pulmonary resections (97.5%) performed at
Aurora Grafton, Aurora Summit and Aurora St. Luke’s in 2015
were video-assisted procedures VATS, a minimally invasive
technique that is used when appropriate to yield the best
possible outcome for each patient.
VATS also may be used with a robotic technique. Minimally
invasive surgery has been shown to decrease length of stay as
well as postoperative complication rates. Aurora Health Care is
able to accommodate the many patients who desire a minimally
invasive approach.
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Most esophagectomies for esophageal cancer in 2015 and 2016 were done using a minimally invasive technique, which decreases
the length of stay, minimizes pain, and decreases recovery time.
Thoracic surgeons from Aurora Medical Center in Grafton, Aurora St. Luke’s Medical Center, and Aurora Medical Center in Summit
performed 108 esophageal procedures in 2016.
Aurora Health Care performed exceptionally well for discharge mortality rate following esophagectomy at 0.0% among the patients
who had surgery, which is better than the STS reported value of 2.2%.

Esophageal Procedure Volumes
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Esophageal Procedures by Indication
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BY THE
NUMBERS
Lobectomy In-Hospital Mortality (Percent)
2014 - 2016
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39

ADVANCED HEART
FAILURE THERAPIES
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The Center for Advanced Heart Failure Therapies (AHFT) offers
lifesaving options for end-stage left and right heart diseases. We
compassionately provide the highest quality cutting-edge care
individualized for patients and their families. Our integrated right and
left heart program combines the national expertise of specialists in
pulmonary hypertension treatment and board-certified advanced heart
failure and transplant cardiologists to cover all aspects of heart care.
Treatment options range from medical optimization and enrollment with
our AHFT program to advanced surgical treatments for advanced heart
disease. We are proud to continue the pioneering legacy of heart
replacement therapy in the Midwest, including the artificial heart
program and heart transplantation.

Having performed more than 890 heart
transplantations and having more than

775 artificial heart devices, we are
among the largest and longest-standing
programs in the country.

The Tendick Clinic for Advanced Heart Failure Therapies encompasses
the entire 4th floor of the Galleria Building within Aurora St. Luke’s
Medical Center. Within this clinic, there is a blood draw lab, 12 patient
exam rooms, two echocardiogram rooms, two consultation rooms, and
staff offices for the left and right heart interdisciplinary teams and the
clinical engineers.
The Pulmonary Artery (PA) Pressure Sensor program has continued to
grow since its addition to the AHFT program in 2015. This technology is
implanted in the patient’s pulmonary artery and provides daily remote
pulmonary arterial pressure measurements. This allows our team to
tailor the patient’s medications and interventions based on readings
that were previously only obtained through invasive catheterization
procedures. We have implanted 44 PA pressure sensor devices since
the inception of the program. These patients have had a 61% reduction
in heart failure admissions compared with their pre-implant admissions.
In 2016, the Karen Yontz Center for Cardio-Oncology was created within
the Advanced Heart Failure Therapies clinic. The center was formed
as a partnership between oncology and cardiology. Patients who have
received cardiotoxic chemotherapy are seen in the clinic to assess the
need for preventive care and ongoing testing. Patient care includes
using state-of-the-art technology such as 4-D echocardiography and
robust protocols to help the patient live well.

Our outcomes are equally impressive, and we are the preferred
program for all major insurance providers and the only program
certified by Medicare and Medicaid services to provide all forms
of heart replacement options in southeastern Wisconsin.
An interdisciplinary team is involved with every patient from the point of
referral through each phase of care. Your team will consist of Advanced
Heart Failure and Transplant cardiologists, cardiothoracic surgeons,
physician assistants, advanced practice nurse practitioners, nurse
coordinators, pharmacists, social workers, psychologists, financial
counselors, chaplains, dietitians, engineers, and organ procurement
coordinators. Our holistic approach to patient care is designed to
improve quality and quantity of life.
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BY THE
NUMBERS

ECMO, Heart Transplants, and VADs
by Indication
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Source: Internal Database

This graph shows the total number of patients seen in the
Left Heart Program in 2016.
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2015
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Year
Source: Internal Database

Heart
Transplant

CardioOncology

2016

2,994

This graph displays the volume of ECMOs inserted, heart transplants
performed and VADs implanted by indication at Aurora St. Luke’s
from 2013-2016.

OUTCOMES

One-Year Cardiac Transplant Outcome		
(Solitary Transplants)

The outcomes for our transplanted graft procedures and patient
mortality rates from 1/1/14 to 6/30/16 are listed below and are
better than the expected rates for both. These are the most
recent results available through the Scientific Registry of
Transplant Recipients (SRTR) website.

1/1/2014 - 6/30/2016				
*Retransplants excluded from patient survival

Survival (%)

Our Kaplan-Meier Survival curve			
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AT A
GLANCE
INNOVATION & EDUCATION

10

14

heart failure
projects

pulmonary
hypertension
clinical trials

17

abstracts/posters
published

44

8

manuscripts
published for
peer-reviewed
journals

The Center for Advanced Heart Failure Therapies is a
sought-after site for the most innovative bench-to-bedside
research programs. Internally funded and collaborative efforts
have yielded information that meaningfully impacts patients’
lives. In 2016 alone our program published one book chapter,
17 abstracts and posters at national and international
meetings, and eight manuscripts for peer-reviewed journals.
We are actively enrolling patients in the most cutting-edge
clinical projects. In total, we are enrolling patients into 14 heart
failure projects and 10 pulmonary hypertension clinical trials
and registries.
Training the next generation of clinicians is an equally
important program initiative; we have a highly sought-after
one-year American Board of Internal Medicine accredited
Advanced Heart Failure and Transplant Cardiology fellowship
program. In addition to knowledge-based expertise,
cardiologists accepted to this program will be taught to work
in a highly integrated team, which we believe is the future of
patient care and medical training.
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Pulmonary Hypertension Clinic
The Accredited Pulmonary Hypertension Clinic at Aurora St. Luke’s Medical Center is a multidisciplinary specialty clinic for the diagnosis and
management of all forms of pulmonary hypertension. We have over 30 years of experience and use all treatment modalities with a holistic approach.
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AT A
GLANCE
Etiology of PH in Pregnant Patients
This graph explains the etiology of pulmonary hypertension in our
pregnant patients.
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VASCULAR
SERVICES
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Aurora Health Care provides a multidisciplinary
approach to diagnosing and treating all types of
vascular disorders. Our specialized Vascular Team
is a multidisciplinary team experienced in
performing multiple vascular interventions, some
of which are not available elsewhere in Wisconsin.
Our experts include vascular medicine specialists,
vascular interventionalists, and vascular and
cardiovascular surgeons who work closely with
one another to provide the best possible care
and outcomes.
Our entire team is located throughout the system to better serve
each of our patient service markets. Our wound care services are
the largest in the state. We have eight locations with hyperbaric
treatment and 12 sites with wound care services. This collaboration
has improved our patients' outcomes.
BAYCARE
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At Aurora Health Care, we consistently perform more endovascular repair
procedures than open repair procedures.

AT A
GLANCE
Abdominal Aortic Aneurysms (AAA)
Types of Repair
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Abdominal Aortic Aneurysm (AAA)
Repair Volumes by Year
2012 - 2016
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AORTIC DISSECTIONS
The vascular team can quickly assess, treat, and follow up with patients
presenting with both acute and nonacute abdominal aortic aneurysms.
Surgeons and interventionalists are able to use minimally invasive
endovascular techniques to repair both stable and rupturing aneurysms.
The use of infrarenal stent grafts has increased over the years as an
alternative to conventional surgery with a shorter inpatient stay and shorter
recovery time. More complex abdominal aneurysms involving the renal
arteries can be repaired using a fenestrated stent, which is a custom-made
stent graft to accommodate the patient’s specific anatomy. More complex
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abdominal aneurysms that are not suitable for endovascular repair
are repaired by our vascular surgeons using a conventional open
abdominal repair. Acute aortic dissection or impending ruptures are taken
immediately to surgery and can be repaired by either conventional or
endovascular procedure.

PERIPHERAL ARTERY DISEASE

BY THE
NUMBERS

Aurora Health Care’s multidisciplinary team of vascular interventionalists,
vascular surgeons, wound care physicians, cardiologists, and
interventional radiologists are highly skilled at performing a number
of procedures to treat peripheral artery disease. These include
procedures to the lower extremity, carotid arteries, and visceral arteries.

LOWER EXTREMITY PROCEDURES
Lower extremity atherosclerotic disease interventions are treated by
endovascular means or by traditional surgical repair.

Peripheral Vascular Intervention (PVI)
Volumes by Year
2012 - 2016
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CAROTID PROCEDURES

VASCULAR QUALITY INITIATIVE

practices in vascular interventions. The VQI is governed by the Society for
Vascular Surgery Patient Safety Organization (SVS PSO), which provides
oversight of data-sharing arrangements, key outcome and quality measure
analyses, and dissemination of information to participating providers. The
VQI encourages vascular surgeons, cardiologists, radiologists, and other
specialists who perform the vascular procedures collected in the VQI to join
this important quality initiative.

The Vascular Quality Initiative (VQI) is a collaborative of regional quality
groups collecting and analyzing data in an effort to improve vascular care.
The VQI collects perioperative and one-year follow-up data to generate
real-time benchmarked reports to assess quality of care and determine best

Aurora Health Care is dedicated to quality of vascular care. It is through our
leadership and participation in this initiative that we can measure and ensure
the highest quality services and outcomes. There are eight vascular
procedures that we measure our quality performance on:

Carotid artery disease is one of the primary causes of transient ischemic
attack (TIA) or stroke. Aurora Health Care’s interventional and surgical
specialists are highly proficient at endovascular and surgical carotid artery
repair with excellent post-procedure results. Endovascular stent placement
is less invasive and may be indicated in select cases.

Carotid Endarterectomy
Volumes by Year
2012 - 2016
350

175

0
2012

2013

2015

2014

2016

Year
Source: VQI Registry

54

Carotid endarterectomy

Endovascular AAA graft

HYBRID PROCEDURES

Carotid stent

Open AAA graft

Peripheral vascular interventions (PVI)

Thoracic endovascular graft

Peripheral bypass grafts

Amputation

Aurora Health Care vascular surgeons and interventionalists perform hybrid
procedures that include surgical procedure, such as an
endarterectomy, followed by an endovascular procedure such as balloon
angioplasty and stent placement. Two new state-of-the-art hybrid suites
accommodate both the vascular surgeon and interventionalist in jointly
performing these specialized procedures seamlessly.

Carotid Artery Stenting
Volumes by Year
2012 - 2016
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THORACIC AORTIC
PROGRAM
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OUR MISSION
2

1

The Aurora Heart & Vascular Program developed a dedicated
program for treating diseases of the thoracic aorta. Aurora Health
Care’s focus on integrated care, heart and vascular expertise,
adoption of state-of-the-art technology, and the current lack
of dominant aortic centers in the region allow Aurora
			
to be positioned as a regional, national, and global
			
leader in this field.

ADVANCE

3

The program offers the most cutting-edge treatments available, with use
of hybrid technology, minimally invasive approaches, and endovascular
work. Recognizing that aortic diseases have a strong genetic and familial
component, the program focuses on care across generations.

Advance the science of
aortic disease by creating
a registry with plans for
nationwide participation
and understand surgical
and non-surgical
outcomes

DELIVER
Deliver the highest
patient-centered
quality care available

FOCUS
Focus on education
through fellowship
training in aortic surgery
and community and
provider education
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WHAT TYPES OF PATIENTS CAN THE AORTIC PROGRAM SERVE?
Diseases of the aorta represent a combination of some of the most life-threatening, yet insidious
conditions we face. The aorta is the main conduit that channels blood away from the heart and to
the rest of the body. Conditions fall into one of two main types:
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1. Acute, which represents immediately life–threatening aortic
emergencies such as dissection, rupture or transections.

2. Chronic, which consists of mostly aneurysmal disease and predisposes
patients to rupture, dissection, and aortic valvular insufficiency

		
		
		
		
		

		
		
		
		
		

Aortic dissection is one type of acute catastrophic event
with certain types having a mortality rate of 2%/hour after
diagnosis and occurs with an incidence of 15/100,000
person-years, which puts it on par with diseases such as
non-Hodgkin’s lymphoma or cervical cancer.

1-2% of the population has a bicuspid aortic valve, predisposing
these patients to aneurysmal degeneration (occurs roughly 70%
of the time), a significant health problem that has little awareness,
effective screening, known knowledge of disease progression, and
inconsistent treatments used among health providers.

WHAT SERVICES DOES THE AORTIC PROGRAM OFFER PROVIDERS?
Acute aortic emergencies: Rapid evaluation and treatment of acute aortic emergencies including:
•

Dissections

•

Intramural hematomas

•

Penetrating aortic ulcers

•

Transections

•

Ruptures

•

Rapidly expanding aneurysms

Thoracic aortic disease has become more
Chronic conditions of the aorta:

prevalent. We have performed over 450

•

Comprehensive surveillance clinic

•

Genetic aortopathy clinic

procedures since 2013.

TAA

Surgical treatment of aortic aneurysms from
root to abdominal aorta:
•

Valve sparring root replacement

•

Aortic valve repair/replacement

•

Ascending aortic replacement

•

Aortic arch work

•

Hybrid aortic operations

•

Endovascular repair of thoracic and abdominal aortic aneurysms

•

Minimally invasive aortic surgery

•

Thoracoabdominal aortic repair
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Aurora’s thoracic aortic aneurysm procedures (both elective and emergent, including
dissection and/or rupture) have a mortality rate of 3.4%, which is well below the national
average. The elective cases at Aurora have a mortality rate of 0.7% for 2016.
Operative mortality* rates for all TAA patients, both elective and emergent
(including dissection &/or rupture) in 2016 = 3.4%.
Operative mortality rates for all elective TAA patients in 2016 = 0.7%.
*Operative mortality is defined as death <30 days post procedure.

TAA Procedures by Volume
2013 vs. 2016
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Since 2013, Aurora has seen a 76% increase
in thoracic aortic aneurysm (TAA) procedures.
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TAA Operative Mortality Rate
2016
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CARDIOVASCULAR
IMAGING
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CARDIOVASCULAR SERVICE LINE DIAGNOSTIC IMAGING CAPABILITY
Aurora’s heart & vascular program has a dedicated cardiovascular imaging capability. Diagnostic testing is decentralized in the intimacy of the
physician-based practice location for the convenience and comfort of the patients. Their experience is enhanced by being in the same location
in which their cardiovascular specialists practice. The diagnostic modalities available include:

•

•

Cardiovascular CT. The state-of-the-art GE Revolution™ is positioned
to capture CT calcium scoring, CT angiography of the coronary
arteries, CT angiography of the vascular system, and general
radiology imaging. The 16 cm detector coverage is the largest
available on the market, which allows for less heart rate management.
Dramatically decreased radiation exposure is another feature.
There are 256 detectors that define the images. This technology
is applied for evaluation of TAVR procedures, abdominal vascular
interventions, and noninvasive examination of the coronary arteries,
among other uses.
Dedicated Cardiac PET. Rubidium PET myocardial perfusion
imaging is employed. Aurora is the only one in the region to report
PET myocardial perfusion, regional wall motion, ejection fraction,
and coronary blood flow. Improved imaging as compared to
traditional SPECT myocardial perfusion imaging is a significant
benefit. This is especially useful for larger patients as well as other
clinical presentations. Again, dramatically reduced radiation exposure
is possible with PET as well as a four-fold reduction in overall
procedure time for the patients.

•

SPECT Myocardial Perfusion. SPECT myocardial perfusion studies
comprise 50% of all nuclear medicine procedures performed
nationwide. Using conscientious patient selection, decreasing patient
radiation exposure is accomplished. The American Society of Nuclear
Medicine set a national goal of decreasing radiation exposure in
50% of the patients. Exposure has been reduced in 90% of patients
in this setting.

•

Echocardiography. A greater than 50% increase in patient studies
has occurred since 2011. There have been many advances that have
occurred over this period of time. 3D, myocardial strain and contrast
imaging are enhancements that have contributed greatly to the
management of patients with conditions from congenital to
oncologic while utilizing state-of-the-art technology. Aurora has one
archive for all echocardiogram images and reports allowing for
universal access across the system from any location. Numerous
quality measures have been implemented to maintain a high quality
service such as weekly educational conferences, a monthly system
practice meeting, report turnaround time deadlines, physician peer
review, and critical results reporting. In 2016, over 30 manuscripts,
reviews, and book chapters were published. The laboratory is
recognized by MedAxiom as a high performing laboratory.
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Echocardiography Procedural Volumes

Transthoracic
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•

Vascular Ultrasound. The physician-based practice is the site for the
comprehensive imaging of the cardiovascular system. It is the sole
focus of diagnostics in the department. The most routine and
challenging imaging of the arterial and venous systems is performed.
The images are uniquely stored in a dynamic versus static format to
allow for the interpretation of cine studies. Vascular medicine
physicians, interventional radiologists, and vascular surgeons are
located there for expert, dedicated patient care.

•

Other Imaging. Additional nuclear procedures include the 		
evaluation of amyloidosis, myocardial viability and radionuclide		
ventriculography. Enhancements to echocardiography are pioneered
routinely. CT coronary artery studies are amenable to fractional flow
rate determination.

Transesophageal

7,762
1,083

Total
Volume

Stress Testing. Stress performance is an integral part of both
nuclear and echocardiographic imaging. These tests can be exercise,
pharmacologic, or a combination. Stress testing also stands alone
as the most basic cardiac diagnostic tool. Functional performance
or rhythm analyses are adjuncts to the evaluation of standard stress
electrocardiograms for ischemia.

64,260
4,284

Stress

•

77,389

Pediatrics

65

AURORA
SPECIALTY CLINICS
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Aurora Health Care is a leader in the treatment of complex
heart conditions. Our cardiovascular specialty heart center
serves patients with hypertrophic cardiomyopathy, adult
congenital heart disease, Marfan syndrome, and valvular heart
disease. Dr. A. Jamil Tajik, an internationally recognized expert,
heads the centers and leads a multidisciplinary team of
specialists who coordinate patient care. Our experts include
cardiologists, nurse practitioners, electrophysiologists,
surgeons, interventional cardiologists, and geneticists
working together to provide patients with best practices
and state-of-the-art care. In 2016, the center evaluated
1,800 patients.
Hypertrophic cardiomyopathy is a genetic condition that
affects one in 500 individuals in the general population. In
these individuals, the heart muscle becomes abnormally thick
and can interfere with the blood flowing out of the heart.
This can affect individuals at any age. We also care for
patients who have inherited cardiomyopathies, familial
cardiomyopathies, and arrhythmogenic cardiomyopathies.
Symptoms of cardiomyopathy can include chest pain,
shortness of breath, palpitations, and fainting. The
hypertrophic cardiomyopathy center offers the best imaging
technology available. Further diagnostic testing may include
cardiac MRI, exercise stress testing, Holter monitor testing,
and genetic testing. With the proper diagnosis, evaluation,
and treatment, a patient’s outlook for living with hypertrophic
cardiomyopathy is excellent and they should be able to lead
a normal life with no significant problems. If septal reduction
therapy is indicated, we do both alcohol septal ablations and
septal myectomies at Aurora St. Luke’s Medical Center. We
perform approximately 10 cases of each per year. We had
420 patient visits in our hypertrophic cardiomyopathy
program in 2016.
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Overall Cardiac Specialty Clinic Visits
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Alcohol Septal Ablation
Volumes by Year

ICD Implants in Patients with
Hypertrophic Cardiomyopathy
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Adult congenital heart disease encompasses at least 30 conditions
that can be diagnosed in infancy or later in life. This defect occurs
before birth. We have expertise in this area and can provide care for
complex congenital conditions. Our multidisciplinary team can offer
treatment options or interventions to help patients lead a longer life.
We have expertise in imaging including cardiac MRI and CT imaging
to further help with diagnosis and development of treatment plans.
We had 422 patient visits in our adult congenital heart disease clinic in
2016.

Adult Congenital Heart Disease Diagnosis
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Adult Congenital Heart 				
Disease Intervention
Volumes
2014
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VSD Repair

Aortic Procedure

Marfan syndrome is an inherited connective tissue disorder that can affect heart valves or enlarge the aorta. Usually people with Marfan syndrome are tall,
thin, and have joint flexibility. We also care for individuals who have associated or inherited aortopathies. Aortopathies are a major cause of morbidity and
mortality. Advanced imaging, including cardiac MRI/MRA and CT scans, is used to monitor and evaluate these individuals. Aurora Health Care had the
opportunity to provide care for 94 patients in 2016.
Valvular heart disease is the second most prevalent cardiac disease after coronary artery disease. At the specialty center, we do advanced imaging to
better help patients determine the need for and timeliness of an intervention, either surgical or medical.
The cardiovascular specialty center is unique in the area of genomic medicine. We offer genetic testing for our cardiomyopathy and aortopathy patients,
which can help us better care for them and also their family members who may have inherited the condition. We have advanced imaging using 2-and 3-D
Doppler. We also use cardiac MRI and CT imaging in selected cases.

Marfan Syndrome Clinic Visit
Volumes
2012 - 2016
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In addition, we also perform device (ICD or pacemaker) optimization in our clinic with the assistance of the electrophysiology team. Small changes can be
made to improve the hemodynamics of the patients and improve their outcomes and symptoms.
Channelopathies are diseases that involve the dysfunction of an ion channel or the proteins that regulate them. These can either be congenital (from birth)
or acquired. We have a team of specialists including physicians, nurse practitioners, genetic counselors, and pharmacists.
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CARDIAC
REHABILITATION
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PREVENTIVE CARDIOLOGY AND REHABILITATION
Cardiac rehabilitation is a medically supervised program designed to
help cardiac patients restore their health—physically, physiologically,
and socially. Rehab focuses on heart-healthy eating, long-term
strategies for weight loss, exercise, managing stress, improving
moods, and quitting smoking.
Cardiac rehabilitation is handled by a team of health professionals led
by a medical director and including nurses, exercise physiologists,
dietitians, and health psychologists. Cardiac rehabilitation usually
happens in three phases:

BY THE
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Volumes throughout the System
2015 vs. 2016

2,482

Phase 1 – Inpatient cardiac rehabilitation – Immediately after cardiac
surgery or another treatment, while still in the hospital, a patient
will begin mild exercise to improve his or her strength before going
home. The patient will also receive education and counseling
about risk factors.
Phase 2 – Outpatient cardiac rehabilitation – This usually starts one to
four weeks after the patient returns home. A referral from their doctor
is required for participation. The program includes supervised exercise
at a hospital or clinic. As the patient exercises, we monitor heart rate,
heart rhythm, and blood pressure. Various pieces of exercise
equipment, such as a treadmill, stationary bike, and elliptical machine,
will be used. The participant also will receive group and individual
counseling aimed at modifying risk factors, and will learn more about
physical activity and nutrition; how to quit smoking; how to manage
weight, blood pressure, and cholesterol; and more. Depending on the
diagnosis, insurance (including Medicare) usually covers this portion
of rehabilitation.
Phase 3 – Maintenance – Upon completion of Phase 2, the patient
might want to stay in a supervised program in a hospital or clinic
because it can help to cement the good habits learned and
continue improvement.
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Cardiac Rehab Locations
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AURORA ST. LUKE'S MEDICAL CENTER

AURORA BAY CARE MEDICAL CENTER

AURORA WEST ALLIS MEDICAL CENTER

AURORA BAY AREA HEALTH CENTER

AURORA MEDICAL CENTER IN KENOSHA

AURORA SHEBOYGAN MEMORIAL CENTER

AURORA HOSPITAL OF BURLINGTON

AURORA MEDICAL CENTER IN SUMMIT

AURORA MEDICAL CENTER IN SUMMIT

CLINIC BASED

AURORA MEDICAL CENTER IN GRAFTON

WEST BEND

AURORA MEDICAL CENTER IN MANITOWOC COUNTY

OSHKOSH

AURORA MEDICAL CENTER IN WASHINGTON COUNTY

FOND DU LAC
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AURORA RESEARCH
INSTITUTE
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Aurora Health Care hosts one of the few research centers in
the world devoted entirely to studying the effect of aging on the
cardiovascular system. The Center for Integrative Research on
Cardiovascular Aging (CIRCA) is led by renowned cardiologist
Arshad Jahangir, MD.
With the support of a generous $2 million donation from the late
Sheikh Khalifa bin Hamad Al Thani in 2014, CIRCA’s mission is to
conduct basic, translational, and clinical research on the biology of
cardiac aging, and to develop new ways to predict, diagnose, and
treat age-related cardiovascular dysfunction to preserve wellness and
improve the quality of life of older people.
In Discovery Laboratory at Aurora Sinai Medical Center and the
cardiovascular research laboratory at Aurora St. Luke’s Medical Center,
Dr. Jahangir and the CIRCA team are studying the molecular basis for
the aging heart’s decreased ability to tolerate stress and increased
susceptibility to injury and heart rhythm disorders.
The CIRCA team has presented original research at national
and international conferences.
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This translational research study compared atrial tissue from
middle-aged and elderly patients with a history of AF to a
matched group of patients without AF. The researchers found an
association between AF and a reduction in specific
mitochondrial activity. This study may help identify targets
for therapies that prevent AF.
Discovery chamber-specific difference in humans

20

published
manuscripts or
book chapters

19

published
abstracts

CIRCA researchers published original clinical,
translational and bench research in several
peer-reviewed journals.
Targeting mitochondria to prevent atrial fibrillation
Atrial fibrillation (AF) is the most common abnormal heart
rhythm and increases risk for stroke, heart failure and death.
Research scientist Larisa Emelyanova, PhD, and colleagues
published findings in American Journal of Physiology-Heart
Circulation Physiology defining changes in the function of
mitochondria, which produce energy in cells, associated
with AF.
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Research scientist Farhan Rizvi, PhD, and colleagues published a
paper in American Journal of Physiology-Cell Physiology
identifying differences in responsiveness between cardiac
fibroblasts from the upper and lower heart chambers. Cardiac
fibroblasts, which help repair injured heart tissue by forming scar
tissue, have become an intense research focus in aging-associated
disease. Excessive or patchy scar tissue buildup increases risk for
heart failure and AF. No therapies effectively prevent such scar
formation or progression.
The study results highlight the complexity of atrial and
ventricular tissue function and their responsiveness to injury.
The study provides support for development of therapies
targeting atrial fibroblasts to reduce excessive scar formation
after injury without significantly altering ventricular
fibroblast function.
Finding a potential new cause for scar buildup
Research scientist Gracious Ross, PhD, and colleagues published
a study in Biology Open comparing cardiac fibroblasts from
ventricular tissue of patients with advanced heart failure to
those of healthy patients. The team discovered a new cause for
excessive scar buildup.
This study is an important contribution to medicine as it provides
a potential new target for development of therapies to reduce
fibrosis and progression of heart failure and arrhythmia in
diseased hearts.
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Above: 1. Screen shot from video of beating heart cells. 2. An induced pluripotent stem cell colony on display under microscope.
3.Stacie Edwards and Rosy Joshi-Mukherjee preparing heart cells.

GROWING BEATING HEART CELLS IN A DISH
Research scientist Rosy Joshi-Mukherjee, PhD, and research
technologist Stacie Edwards are building a cell-based program at
CIRCA using induced pluripotent stem (iPS) cell technology. This
revolutionary technology takes Aurora researchers closer to
growing miniature beating heart tissue on which new therapies
for treating cardiovascular disease can be tested in a dish. Use of
this technology may reduce or eliminate the need for experimental
animal models and the controversial use of embryonic stem cells in
the search for new therapies to prevent and treat heart failure.
After launching the cell-based program in late 2015, the team has
made progress implementing the iPS cell technology and
establishing techniques to successfully grow heart cells derived
from reprogrammed iPS cells. The research was presented by Dr.
Joshi-Mukherjee at Gordon Research Conference on Cardiac
Arrhythmia Mechanisms in Ventura, Calif., in February 2017.
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After testing iPS cells for specific markers to ensure the
reprogramming had been successful, Dr. Joshi-Mukherjee and her
team initiated a cardiac differentiation protocol to transform the
iPS cells into beating heart cells that expressed specific cardiac
markers and with electrophysiological characteristics of beating
cells from various chambers of the heart.
To continue this work, Dr. Joshi-Mukherjee received a $50,000
Cardiovascular Surgery Research Award. In the future,
researchers plan to generate iPS cells directly from blood or skin
tissues from Aurora patients, potentially leading to a precision
medicine approach.
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THE TAVR SUCCESS STORY

1,000th TAVR

The journey to bring a new major medical treatment to patients requires
cooperation from a dedicated team of researchers, coordinators,
doctors, nurses and clinical trial participants. The transcatheter aortic
valve replacement (TAVR) procedure represents one success story that
continues as Aurora Health Care physician researchers have become
national experts on this latest advancement.

Since it became available through participation in a clinical trial in 2011,
Aurora St. Luke’s Medical Center celebrated its 1,000th TAVR procedure
Dec. 8, 2016.

What’s TAVR?
TAVR provides a less invasive alternative to open-heart surgery for
patients with severe narrowing of the aortic valve who are unable
to safely undergo surgery because of age or other medical
condition. Left untreated, these patients have a 50 percent risk
of dying at one year.
During the procedure, the physician inserts a new valve into the heart
through an artery using a catheter. Patients spend less time in the
hospital because the chest cavity does not need to be opened.

Aurora’s Role
Aurora Research Institute played a key role in Medtronic Inc.’s CoreValveTM
device being used for the TAVR procedure, participating in clinical trials
that led to US Food and Drug Administration (FDA) approvals in 2014
through 2016.
Aurora has been the only site in the state to participate in the clinical
trials contributing to CoreValve’s approvals and the first site in the
state to commercially offer the CoreValve™ device to patients after
each approval.
In October 2016, the FDA approved the EvolutTM R 34-mm
aortic valve in the CoreValve family, and it is currently the
largest-sized TAVR system available in the US. Aurora
enrolled more patients in this clinical trial than any other
site in the country.
This large valve expands the population that can undergo the
procedure. Previously, patients with larger aortic anatomy would
have had to undergo open-heart surgery.
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A brief ceremony began when cardiologist Tanvir Bajwa, MD, and
cardiovascular and thoracic surgeon Daniel O’Hair, MD, arrived just
moments after completing their latest TAVR case. Drs. Bajwa and O’Hair
have served as local principal investigators for the different clinical trials
studying the CoreValve platform. Paul Werner, MD, and Suhail
Allaqaband, MD, have assisted as subinvestigators for these trials.
No other health system in the country has a team that has performed as
many TAVR procedures together. The team at Aurora St. Luke’s performs
typically eight to 10 TAVR procedures a week with a 100 percent success
rate. Physicians and government officials from around the world have
visited Milwaukee to watch the Aurora St. Luke’s TAVR team in action.

TAVR into the Future
Aurora’s expertise with TAVR will continue as the institute is currently
involved in seven TAVR trials with more to come in 2017. Six of the trials
are studying Medtronic’s CoreValveTM and one is studying Boston
Scientific’s LotusTM Valve System (REPRISE III trial).

No other health system
in the country has a team that has
performed as many

TAVR procedures together.
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PATIENT STORY:
Charles Zern
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One Man's TAVR Experience
Nonagenarian Charles Zern volunteered to enroll in a CoreValve clinical trial in 2013. After having hip surgery in 2010,
the Wauwatosa resident developed atrial fibrillation, an irregular heartbeat, while in the hospital. Less than a year
later, he was rushed to the hospital with heart failure.
Tests determined that Zern had severe aortic stenosis. He had no other major health concerns, and the surgeon
determined that open-heart surgery presented an intermediate risk, despite his age of 88 years. His cardiologist sent
him to Aurora St. Luke’s to see Dr. Daniel P. O’Hair and learn more about the TAVR clinical trial.
Wendy Dunaj, RN, manager of cardiovascular clinical trials, and Deb Waller, BSN, research coordinator, explained the
clinical trial process and answered Zern’s questions regarding participation. Zern qualified for the SURTAVI clinical
trial, but his treatment assignment would be comparable to flipping a coin to either open-heart surgery or TAVR.
After being randomly selected, Zern underwent TAVR on July 8, 2013. Dr. Tanvir Bajwa and Dr. O’Hair performed the
procedure together.
Zern said that he would do it all again in a heartbeat. He is happy that his participation in this clinical
trial could help others. He is about halfway through his clinical trial participation. Researchers will follow
him for another two years.
“I feel fine now, but I get a little short of breath because of the heart failure,” Zern said.
“The best part of the whole experience is that I am still here.”
Zern will celebrate his 92nd birthday in June 2017 and is planning a train trip across the Canadian countryside.
“I wouldn’t be here if it weren’t for Dr. Bajwa and Dr. O’Hair,” Zern said. “They are absolutely the top.
They not only have an interest, they care.”
Zern’s experience should not be used to predict outcomes of the clinical trial or the procedure.
Data collection continues.
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For a medical device to become available for widespread use in the United States, generally it must first
be cleared by the Food and Drug Administration (FDA). Clinical trial results help the FDA determine
whether a device should be cleared. In addition to TAVR (see pages 15-16), Aurora Health Care
participated in clinical trials that led to FDA approval of five other heart health innovations in 2016.

Bioresorbable Stent

Preventing Stroke Recurrence

Aurora St. Luke’s Medical Center became one of the first sites in the nation
to implant the Abbott Absorb bioresorbable stent, approved by the FDA in
July 2016 for patients with coronary artery disease. Affecting 15 million
people in the US alone, coronary artery disease is the leading cause of
death worldwide.

Blood clots can travel to the brain through a hole in the
heart called a patent foramen ovale (PFO) and cause
stroke. This hole often isn’t found until a stroke has
occurred. For more than 10 years, Aurora researchers
have participated in clinical trials to study PFO closure
devices, including the St. Jude Medical Amplatzer PFO
Occluder, hoping to reduce stroke recurrence.

Aurora researchers first studied the stent through a Phase III clinical trial
sponsored by Abbott (clinicaltrials.gov identifier: NCT01751906). Aurora
St. Luke’s was the only site in the state to participate in the trial. Now the
stent is available for widespread use.
“It [the bioresorbable stent] supports the artery for a
period of time and then, in about three years, it
dissolves and disappears,” said Suhail Allaqaband, MD,
local principal investigator. “A game changer in the
treatment of clogged arteries.”
Before the advent of the bioresorbable stent,
interventional cardiologists used only metal stents for
clogged arteries. Metal stents remain in place for the
rest of the patient’s life, oftentimes restricting vessel motion.
Dr. Allaqaband said the lack of metal will simplify future heart
surgeries while promoting healing and enlarging the artery.
Data collection for the clinical trial continues. Don Lobacz, RN,
is site coordinator.

In October 2016, the FDA approved the use of the
occluder, a device implanted nonsurgically, and
in mid-November, interventional cardiologist Tanvir Bajwa, MD, became the
first in Wisconsin to implant the approved device.
“The recent FDA approval of the PFO Occluder brings new hope for
patients ages 18 to 60 with cryptogenic stroke who may be seeking
alternative treatment options for prevention,” Dr. Bajwa said. “Being the first
hospital in the state to provide this new device to patients builds on our
commitment to innovation and providing the best in patient care.”
Dr. Bajwa is the local principal investigator at Aurora St. Luke’s for the
Amplatzer trial (clinicaltrials.gov identifier: NCT00465270). He and
Dr. Allaqaband have served as local principal investigators at Aurora St.
Luke’s for two additional PFO clinical trials. Aurora enrolled the most subjects
of any site for two of the three studies. In the third trial, Aurora enrolled the
second most subjects.
Data collection for the clinical trials continues. Deb Waller, BSN, is
site coordinator.
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Gore Excluder ® Iliac Branch Endoprosthesis

Micra Transcatheter Pacing System

With participation by Aurora St. Luke’s, W.L. Gore and Associates proved
the safety and effectiveness of the Gore Excluder® Iliac Branch
Endoprosthesis to the FDA, receiving approval in February 2016 to make
the device commercially available. Interventional
radiologist Mark Mewissen, MD, led the clinical trial
at Aurora St. Luke’s to evaluate this first-of-its-kind
device for endovascular treatment of aneurysms in the
common iliac or aortoiliac arteries, which are
located in the abdominal area (clinicaltrials.gov
identifier: NCT01883999). Aneurysms are ballooning
and weakening of the arteries. This device allows for
preservation of flow in the internal iliac arteries, and
important circulation to vital structures in the pelvis.
Nicole Baecker, BSN, is site coordinator.

In April 2016, the FDA approved the Micra Transcatheter
Pacing System (Medtronic Inc.), the first pacemaker
that doesn’t require surgery, and reduces device
pocket infections. The device, about the size of a nickel,
is implanted directly in the right ventricle via a minimally
invasive procedure through a vein in the leg. Serving as
principal investigators at Aurora St. Luke’s, cardiac
electrophysiologists Dr. Sra and Vikram Nangia, MD,
were the first in Wisconsin to implant the miniature
leadless pacemaker as part of a clinical trial (clinicaltrials.gov identifier:
NCT02004873). Anthony Chambers, BSN, is site coordinator.

Navik 3DTM
With support and backing from Aurora, APN Health, LLC in February 2016
received FDA clearance to market its advanced three-dimensional cardiac
mapping system, Navik 3DTM. Development of the Navik 3DTM system was a
collaborative effort led by renowned Aurora cardiac electrophysiologist
Dr. Jasbir Sra, MD. The system reduces cost and complexity of
electrophysiology procedures by providing real-time 3D maps that provide
catheter location in the heart. Navik 3DTM is the first cardiac mapping
system that doesn’t require specialized equipment. Instead it uses the
patient monitoring and fluoroscopic imaging systems already present in
electrophysiology laboratories.

Dr. Jasbir Sra (left) collaborates during a procedure
in the electrophysiology suite.
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Clinical Trial Highlights
Researching Regeneration of Diseased Heart Muscle
Aurora St. Luke’s Medical Center is the only site in Wisconsin conducting
the Phase II ALLSTAR trial sponsored by biotechnology company Capricor
Inc. (clinicaltrials.gov identifier: NCT01458405). Local principal investigator
Tanvir Bajwa, MD, is testing the safety and effectiveness of cardiac stem cells
derived from donors unrelated to the recipients, CAP-1002, in regenerating
heart muscle and reducing scar size in subjects who have had a heart attack.
A heart attack damages, or scars, heart muscle, which increases the risk of
heart failure. Clinical trial subjects are randomly assigned to receive the
investigational cardiac stem cell therapy or a placebo. Because the process
is blinded to avoid scientific bias, the physician, caregiver and patient do
not know whether the study therapy or placebo was used. Investigators will
follow the study subjects for up to five years to determine the safety of the
treatment and whether the scar, or infarct, size has decreased in those who
received the stem cells compared to those who did not. Dena Burke, BSN, is
coordinating the trial for Aurora.

Studying Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH), a rare but serious condition, causes
pressure in a patient’s pulmonary arteries to become critically high. Aurora
St. Luke’s is the only site in Wisconsin to participate in the Multinational,
Multicenter Study to Assess the Effects of Oral Sildenafil on Mortality in
Adults With Pulmonary Arterial Hypertension (AFFILIATE) and was the
first site in the United States to enroll a subject (clinicaltrials.gov identifier:
NCT02060487). Led locally by Dianne Zwicke, MD, this study will assess the
effect of different dosages of oral sildenafil on mortality in adults with PAH.
Pfizer Inc. is sponsoring this Phase IV international study. The trial
coordinators are Linda Boehm, RN, and Kelsey Krueger.
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Hundreds of patients enroll in cardiovascular
trials at Aurora Health Care each year. 		
Available clinical trials study treatments and
devices for the spectrum of heart diseases.
Aurora St. Luke’s is one of 30 sites across the US participating in a national
registry trial conducted by the University of California-San Diego for patients
with chronic thromboembolic pulmonary hypertension (CTEPH), which is
high blood pressure in the pulmonary arteries that lasts six months or more
(clinicaltrials.gov identifier: NCT02429284). Led locally by Dr. Zwicke, the
registry will track at least 750 subjects with a new CTEPH diagnosis over the
next six years. The registry will foster understanding of the disease,
treatment responses and improvement of care for patients with CTEPH.
Linda Boehm, RN, is the local coordinator.

Tailoring Antiplatelet Drug Decisions to			
Individual Genetics
After receiving a stent, patients will take antiplatelet medication to
prevent blood clots from forming. Studies have suggested that patients with
a certain genetic liver enzyme abnormality may not respond as well to the
currently approved antiplatelet medication, clopidogrel. A newer antiplatelet
drug, ticagrelor, works regardless of the abnormality, but is more expensive
and requires more frequent doses. As part of the TAILOR PCI trial, local
principal investigator Louie Kostopoulos, MD, is studying whether or not
genetic testing can identify the best antiplatelet therapy for patients who
receive a coronary stent (TAILOR-PCI, clinicaltrials.gov identifier:
NCT01742117). This Phase IV trial is sponsored by Mayo Clinic and
National Institutes of Health. Dena Burke, BSN, is coordinating the trial at
Aurora St. Luke’s.
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cardiovascular clinical trials open to accrual
and follow-up as of Dec. 31, 2016

"Wrapping-up" Devices to Reduce Infection
Devices such as pacemakers and implantable cardioverter-defibrillators
can become infected. Local principal investigator Vinay Mehta, MD, joined
Medtronic Inc.’s global study evaluating the TYRX™ Absorbable Antibacterial
Envelope’s effectiveness in reducing major infections following
cardiovascular implantable electronic device procedures (clinicaltrials.gov
identifier: NCT02277990). This postmarketing study tracks subjects’
occurrence of a major infection over one year. Alex Albers is coordinating the
trial at Aurora BayCare Medical Center.

Providing Expert Input for Latest Imaging Devices
Aurora St. Luke’s is the only site in the nation providing clinical evaluation of
GE Healthcare’s Vivid IQ, Vivid E95 and LOGIQ E9 ultrasound systems. Vivid
E95 is looking at the highest resolution four-dimensional ultrasound
imaging. Principal investigator Bijoy Khandheria, MD, is providing feedback
on workflow, performance, user preference, image quality and device
features. Research coordinator Kathy Schmidlkofer is providing site
coordination. Vivid and LOGIQ are trademarks of General Electric company.

585

new subjects enrolled in cardiovascular
clinical trials in 2016
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Grant Awards

Acknowledgements

With more than $750,000 in external and internal grant awards, Aurora Health Care researchers launched
new and continued existing cardiovascular research projects.
External Funding

Award Highlights

2016 EXTERNAL AWARDS
Smarter management and resource use for today’s
complex cardiac care (SMARTCare)
Investigator: Kenneth Phillips, MD
$225,735 (continuing support)
Centers for Medicare and Medicaid Services subaward
from American College of Cardiology Foundation

Chemotherapy drugs, such as anthracycline, though effective in
combating cancer, can cause damage to the heart that may lead to
death. Advanced heart failure and transplant cardiologist Vinay Thohan,
MD, hypothesized that the reason for the damage may partially lie in the
patient’s genetic structure.

Predictive optimal anticlotting treatment for
segmented patient populations
Investigator: Kourosh Ravvaz, MD, PhD
$120,221 (continuing support)
National Institutes of Health subaward from Harvard University

$456,647

This project aims to better identify which patients are more susceptible
to cardiotoxicities from chemotherapy, allowing oncologists to design
patient-centered treatment plans.

Predicting risk of cardiotoxicity in cancer patients undergoing
chemotherapy incorporating genetic signatures
Investigator: Vinay Thohan, MD
$80,000
Greater Milwaukee Foundation
Using systems science methods to study cardiac risk
in the Somali community
Investigator: Ahmed Dalmar, MD
$20,691 (continuing support)
National Heart, Lung, and Blood Institute subaward
from HealthPartners Institute for Education and Research
Biomarkers to identify patients at high risk for heart failure
after cardiac surgery
Investigator: Farhan Rizvi, PhD
$10,000
David V. Uihlein Foundation
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Dr. Thohan and his team are assessing 14 years of data to identify which
patients treated with anthracyclines developed heart damage. DNA
from these patients stored in Aurora’s Biorepository and Specimen
Resource Center will allow the researchers to assess whether any of
more than 100 gene variants associated with heart damage correlate
with cardiac outcomes.

This study is supported by an $80,000 grant award from
Greater Milwaukee Foundation.

received in 2016
from federal
and foundation
sources

Transformational Gift
A $1 million gift by anonymous
donors will help influence the next
generation of cardiologists. The
gift will create the Colton Scholar
in Cardiology Research in honor of
Dr. A. Jamil Tajik, which will support
the hiring of research scholars to
spur cardiovascular advances.
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2016 INTERNAL AWARDS
Sullivan Cardiac Research Award for Residents and Fellows
Up to $30,000 each
Echocardiographic mechanisms of left ventricular thrombus formation
among patients with heart failure with reduced ejection fraction: the role of
strain analysis assessed by two-dimensional speckled tracking
Investigator: Dhruv Chawla, MD
Therapeutic approach to implantable hemodynamic monitoring: A
timing-based strategy
Investigator: Shankho Ganguli, MD
Cardiac Research Award
Up to $40,000 each
HeartQoL validation in patients with ischemic heart failure
Investigator: Nasir Sulemanjee, MD
Protein phosphatases PP2A and PPMIA in ventricular fibroblasts as potential
targets for ventricular fibrosis prevention in heart failure
Investigator: Farhan Rizvi, PhD

Aurora Cardiovascular Services Research Support Fund
Up to $2,000 each
Oral presentation – Expeditious reperfusion in non-ST segment elevation
myocardial infarction: A single center 10-year experience at International
Academy of Cardiology Annual Scientific Sessions
Investigator: Shetabi Kambiz, MD
Oral presentation – Drug-eluting devices in femoropopliteal disease:
Trends of use and patient outcomes at Transcatheter Cardiovascular
Therapeutics
Investigator: Daniel Ortiz, MD
Poster presentation – Recovery of left ventricular mechanics following
transcatheter aortic valve implantation at American Heart Association
Scientific Sessions
Investigator: Daniel Harland, MD

Award Highlight

A novel strategy to protect against dronedarone-induced myocardial
dysfunction in the failing heart (second-year continuation)
Researcher: Larisa Emelyanova, PhD

Although many patients with congestive heart failure are treated with blood
thinners, no definitive recommendation exists to minimize the risk of clotting
in patients who do not have pre-existing indications.

Cardiovascular Surgery Research Awards
Up to $50,000 each

Mentored by interventional cardiologist Tanvir Bajwa, MD, and advanced
heart failure and transplant cardiologist Vinay Thohan, MD, fellow
Dhruv Chawla, MD, will use echocardiography to analyze variation in the
heart’s contraction to determine factors leading to the formation of clots
inside the heart.

Effect of age-associated epigenetic memory on human-induced pluripotent
stem cell-derived cardiomyocytes differentiation and maturation
Investigator: Rosy Joshi-Mukherjee, PhD
Dedifferentiation of cardiac myofibroblasts to fibroblasts as a strategy to
mitigate cardiac fibrosis and progression of heart failure
Investigator: Gracious Ross, PhD, DVM
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Autoantibodies to angiotensin type 1 receptor in cardiac transplant candidates: Do pre-existing antibodies have a role in long-term outcomes?
Investigator: Martin Oaks, PhD

Identifying these subtle differences may help clinicians determine which
patients would benefit from blood thinners.
This study is supported by a $30,000 Sullivan Cardiac Research Award for
Residents and Fellows. The Sullivan research award is possible thanks to a
generous $1 million gift from Vivian and Tim Sullivan to support the research
of Dr. Bajwa via the fellowship program.

Funds are available because
of the generosity of donors

$304,485

to Aurora Health Care

Foundation

awarded
by Aurora
Research Institute
in 2016 to
Aurora Health Care
investigators
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PATIENT STORY:
Alan Sanford
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My Best Day is Today
In the second half of 2012, after having a ruptured mitral valve repaired more than five years earlier and enduring one
heart attack and chronic heart failure, Greendale resident Alan Sanford, then 70, was at the maximum age for heart
transplant. Not considered high enough risk to be placed on the waiting list, he seemed to be out of options.
Or was he?
In February 2007, while his wife, Adelle Sanford, was out of town, Alan found himself panting and out of breath while
taking a short walk down his driveway to take out the trash. When Adelle, a registered nurse at Aurora St. Luke’s
Medical Center, returned, she encouraged him to see a cardiologist who told Alan that he had a
ruptured mitral valve, the dual-flap valve that helps facilitate the flow of blood into the left ventricle of the heart.
A few weeks later, Alan had the valve repaired, but during one of the subsequent follow-up visits, it was discovered
that he had also had a silent heart attack. He then received a Holter monitor, a portable device that continuously
measures and records the heart’s activity.
In July 2007 while playing volleyball, a sport Alan and Adelle had enjoyed for almost 35 years, Alan passed out on
the sand in cardiac arrest. Adelle lifted his chin to open his airway and was ready to begin cardiopulmonary
resuscitation, when he spontaneously returned to consciousness.
“When I came to, I said, ‘I think I can finish the game,’” Alan said. But the paramedics had arrived, and took him to the
emergency department. The doctors there received information from the Holter monitor that helped them swiftly
make treatment decisions.

Clinical trial
subject shares

decade-long
experience with
heart disease.

Later in the month, Alan received a pacemaker and stent. He began cardiac rehabilitation. His health remained
relatively steady for almost three years. However, in May 2010, he suffered a ventricular tachycardia, which means his
heart rate became dangerously high. He then needed a stent repair in mid-June. At this point, Alan had grown tired
of and from his heart problems.
Interventional cardiologist, Suhail Allaqaband, MD, suggested that Alan consider a heart transplant.
“That was second only to hearing the big C-word,” Alan said. He then visited Nasir Sulemanjee, MD, a member
of the Aurora St. Luke’s Heart Failure and Transplant team, to learn more about transplantation, but Alan was at the
maximum age of 70 for a heart transplant, and his heart was not considered a high enough risk to put him
on the waiting list for a transplant.
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Taking a Chance

Celebrating Today

Then Dr. Sulemanjee suggested a clinical trial using stem cells for heart
failure that was being conducted at Aurora. DREAM HF-1 is a double-blind,
placebo-controlled, Phase III study designed to test the safety and effectiveness of a new stem cell therapy known as rexlemestrocel-L in people with
chronic heart failure compared with subjects who do not receive the stem
cells (clinicaltrials.gov identifier: NCT02032004). Dr. Sulemanjee is the local
principal investigator.

Alan will not know whether he received a placebo or the stem cells until the
study has completed, but he has had no cardiac-related incidents since
the infusion.

Stem cells may be capable of repairing damaged tissues due to their
regenerative abilities. The stem cells in the DREAM HF-1 study are
manufactured from the bone marrow of healthy donors and injected
into damaged heart tissue.
Alan decided to pursue the study, but did not initially qualify for enrollment
because his heart failure was not severe enough. However, seven months
later in August 2015, Alan developed a case of pulmonary edema and went
to the emergency department. Pulmonary edema is caused by extra fluid in
the lungs and can make it difficult to breathe.
Alan called the Aurora research coordinator for the study, Don Lobacz, RN,
who determined that Alan qualified for the DREAM HF-1 study. On October
14, 2015, Sanford received his injection.

“Fairly quickly, I started feeling much, much better,” Alan said. “I was also
aware that there could be a placebo effect.”
Before receiving the infusion, Alan’s heart ejection fraction, a test that measures the amount of blood leaving the heart as it contracts, was 20 percent.
Three months afterward, his ejection fraction had improved to 30 percent.
Normal ranges from 55 to 70 percent.
Alan turned 75 in May 2017. He and Adelle celebrated 50 years of marriage
in January 2016. They enjoy traveling around the United States to visit their
three children and seven grandchildren.
“I am very lucky,” Alan said. “Before the procedure, tomorrow was always my
best day. I will do that tomorrow, I would say. Now my best day is today.”

Sponsored by Mesoblast Inc., the clinical trial is ongoing. Alan’s experience
should not be used to predict outcomes of the clinical trial. Rexlemestrocel-L
is an investigational agent and is being evaluated in clinical trials.

“This is a double-blind study, so you don’t know if you are going to get
the stem cells or not,” Alan said. “I was told that when I went through the
procedure, I would go to the operating room, they would insert the catheter,
and the doctor will go through the whole routine that he would go through
whether or not I received the stem cells.”

Stem cells may be capable of
repairing damaged tissues due
to their regenerative abilities.
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Physician Highlight
Research that Never Skips a Beat
When David Kress, MD, came to Aurora St. Luke’s Medical Center in the
early 1990s he fell into a rhythm of day in and day out heart surgery.
But a heart condition he’d studied in his residency kept needling him ...
atrial fibrillation.
His persistence in pursuing ways to address the disease has led to a career
dedicated to cardiovascular research and innovation.

From the Start
Atrial fibrillation (AF) is an irregular heartbeat that can lead to stroke and
heart failure. More than 5 million people in the US have the condition.
Early in his career, Dr. Kress served as principal investigator for several
major clinical trials to study AF. As a result, he experienced a series of
clinical milestones that include being one of the first in the state and, in
some cases, the nation to perform increasingly complex ablation techniques
to eliminate AF.
“I was in at the very beginning of the surgical ablation era, and that has
matured into something that almost every surgeon does. At the time, only
a handful of surgeons in the world were doing it. To me, that has been the
most fulfilling part of being involved with research,” said Dr. Kress, who is
director of the Surgical Arrhythmia Program at Aurora St. Luke’s.
Today, Aurora St. Luke’s is the only hospital in Wisconsin and one of only a
few in the nation to offer the hybrid ablation technique pioneered by
electrophysiologist Jasbir Sra, MD, and Dr. Kress. To perform the hybrid
technique, an electrophysiologist and cardiothoracic surgeon work together
to ablate the heart to restore its normal rhythm. The surgeon’s ablations
occur outside of the heart, while the electrophysiologist uses a catheter
inside of the heart to create scar tissue. The two ablations block the
electrical pathways that are causing the irregular heartbeat.
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Not Just AF
To date, Dr. Kress has participated in over 50 clinical trials and has lectured
on surgical innovations in cardiac electrophysiology at major scientific
meetings throughout the US, Canada, Europe and Asia.
He has authored and reviewed numerous papers and continues
to conduct research, perform surgeries, and serve on scientific
committees and advisory boards.
Over the years, Dr. Kress has encountered patients with acute kidney
injury, an uncommon but serious complication after heart surgery. At
Aurora St. Luke’s, he is participating in a Phase II clinical trial to study
whether a gene-inhibiting drug prevents this complication.
The sponsor, Quark Pharmaceuticals, has developed an experimental
compound, QPI-1002, to temporarily stop a natural genetic response to the
trauma of cardiac surgery, allowing time for repair of cellular damage and
prevention of kidney injury. The trial’s purpose is to determine the drug’s
safety and effectiveness (clinicaltrials. gov identifier: NCT02610283).
Dr. Kress’ research interests also include surgically implanted devices. In the
PERIGON Pivotal Trial, researchers are studying the Medtronic Model 400
aortic valve bioprosthesis in patients with aortic valve disease (clinicaltrials.
gov identifier: NCT02088554).
The elimination of AFib will always be a primary area of research for
Dr. Kress. As he explores new surgical innovations in cardiac
electrophysiology, he continues to ensure that hearts don’t skip
a beat and neither has he in his over 25 years at Aurora.

To date, Dr. Kress has
participated in over 50

clinical trials.
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Researcher Highlight
Living Big Data
Precision medicine puts the patient at the center of care. It encompasses
individual genetic and molecular profiles and comprehensive longitudinal
information stored within massive databases and electronic health records to
advance tailored disease prevention and treatment. It means thinking
big data.
In the past two years at Aurora Research Institute, physician-researcher
Kourosh Ravvaz, MD, PhD, has been living big data, devising ways to improve
survival rates, accelerate innovation and lower costs.
“As a physician with several years of experience in clinical practice, I have
always had a vision to develop translational research approaches that would
improve health outcomes and delivery of high-quality care,” Dr. Ravvaz said.
His team has been investigating use of patients’ genotypes to optimize
anticoagulation therapy. Anticoagulants are used to thin the blood, which
helps prevent clot formation, a cause of stroke. Warfarin, a common
anticoagulant, has been challenging for providers because the effective
amount varies greatly between individuals and because many foods and
drugs adversely interact with the medicine.

To develop the schema, a database with medical records of 350,000
patients with more than 20 million patient encounters from a 15-year
period was created. That’s a lot of data. Big data.
“This effort will help keep patients out of the emergency room while
preventing the consequences of stroke,” Dr. Ravvaz said.
This research is being conducted in collaboration with Harvard Medical
School and University of Minnesota. After committing to first-year funding
in 2015, National Institutes of Health renewed its support for the project
with Aurora receiving an additional $120,000 from Harvard. The work
also is supported by Aurora Research Institute’s intramural award program.

Big Data Exploration Requires Big Collaboration
Dr. Ravvaz’s team and senior research programmer analyst Jon Cook
worked closely to identify patient records and ensure the quality of the
cohort-associated data within a de-identified anticlotting research database.
Cook worked continuously with the study team to implement an algorithm
based on previously published work regarding a complex exposure period
and time in therapeutic range. He cross-referenced biorepository
databases to collect available blood specimens.

Newer drugs, called novel oral anticoagulants (NOACs), are costly in
comparison to warfarin and have not been shown to be universally more
effective, but are likely better than warfarin for some people.
“It has been shown that because of a difference in a few genes, one person’s
dose could be 20 times that of someone with otherwise similar clinical
characteristics,” Dr. Ravvaz said. With the help of Aurora Health Care’s
electronic health records and the institute’s Biorepository and Specimen
Resource Center and Research Analytics team, the researchers are
investigating whether a scoring schema incorporating a patient’s clinical
and genotypic information can help clinicians decide between NOACS or
warfarin at the start of treatment.
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Medical records of

350,000 patients
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Cardiovascular Volumes (systemwide)
Source: Aurora Smart Chart

2014

2015

2016

CARDIOVASCULAR SURGERY
Coronary artery bypass graft
(CABG), total
CABG on pump
Valve procedures
Aortic valve replacement
Mitral valve replacement
Other valve replacement
Aortic valve repair
Mitral valve repair
Other valve repair

926

922

941

768

793

816

446
107
19
7
61
8

358
105
19
9
70
16

385
110
19
15
39
23

Peripheral vascular intervention
With stent
Without stent
Non-coronary atherectomy
Endarterectomy
Carotid endarterectomy
Other endarterectomy
Abdominal aortic aneurysm repair
Endovascular
Open
Thoracic aortic aneurysm repair
Endovascular
Open
Lower extremity bypass
Extracranial intervention
With stent
Carotid stent
Other extracranial stent
Without stent

9,446
7,087
2,359
2,571
2,443
2,130
301
12

8,919
6,583
2,336
2,402
2,254
2,031
209
14

9,049
6,529
2,520
2,361
2,206
2,066
132
8

127

146

146

46

57

111

ELECTROPHYSIOLOGY

345

443

426

135

98

112

75
60

58
40

66
46

201

272

334

17

14

26

EP study
Cardiac mapping
Cardioversion
Ablation – percutaneous
Pacemaker/Resynchronization
Pacemaker
Cardiac resynchronization
therapy-pacemaker
Defibrillator/Resynchronization
Defibrillator
Cardiac resynchronization
therapy-defibrillator

HEART FAILURE AND TRANSPLANT
Ventricular assist device

44

2015

2016

1,840
1,000
839
11
504
303
201
172
132
40
99
22
77
175
34
33
28
6
1

2,140
1,052
1,071
37
487
327
160
194
166
28
137
40
97
149
37
28
23
5
9

2,186
1,000
1,107
154
459
327
132
169
147
22
163
38
125
203
51
35
32
3
16

1,129
837
1,185
1,050
1,098
1,005

986
790
1,319
913
1,087
1,000

1,151
880
1,530
863
1,139
1,049

93

87

90

820
595

807
594

903
706

225

213

197

VASCULAR MEDICINE

INTERVENTIONAL CARDIOLOGY
Heart catheterization, total
Catheterization w/ pressures
Angiogram w/o pressures
Coronary intervention
With stent
Drug-eluting stent only
Non-drug-eluting stent only
Both
P
 ercutaneous coronary
intervention without stent
Percutaneous coronary
intervention atherectomy
Myocardial biopsy
Patent foramen ovale/atrial
septal defect closure, total
Open
Closed
Transcatheter aortic valve
replacement (TAVR)
Transcatheter mitral valve
replacement (TMVR)

2014

51

37
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Breaking Records
American College of Cardiology in 2016
accepted 19 Aurora Health Care-authored
abstracts for presentation at its annual
meeting – the most Aurora has ever had
accepted.
Of those 19 studies, 10 were conducted under
the mentorship of Arshad Jahangir, MD,
medical research director of the Sheikh Khalifa
bin Hamad Al Thani Center for Integrative
Research on Cardiovascular Aging.
The number of Aurora-authored abstracts
accepted by American College of Cardiology
have been gradually increasing and jumped to
19 from a previous best of 14 presented each in
2014 and 2015.

19

American College of
Cardiology abstracts
accepted for presentation

Breaking another publishing record, Aurora
researchers presented 10 abstracts at Heart
Rhythm Society’s 2016 annual meeting.
This is the most Aurora has ever had
accepted by Heart Rhythm Society,
formerly known as North American Society of
Pacing and Electrophysiology. The previous
acceptance record was eight for this meeting.

10

abstracts presented at
Heart Rhythm Society's
annual meeting
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